Dividend Win Wednesday: Semiconductor Capital at 89% Off While Insiders Buy Energy

This Week's Setup

Energy and semiconductor capital equipment hold the top two slots, with KLA Corporation trading at an 88.9% drawdown from its 52-week high and a 12.4% free cash flow yield, while insiders at ConocoPhillips bought shares through late June.

The S&P 500 CAPE sits at 38.9, well above the long-run mean, a data point that matters most when free cash flow yields stretch above 5% and payout ratios stay under control, which four of the top eight names deliver this week.

Biotech and pharma occupy three slots, all with insider activity in the past 30 days and FCF yields above 5%.

Quick Scan

The 8 Names

1. ConocoPhillips (COP)

Dividend yield: 3.0% | Payout ratio: 51.3% | 52w drawdown: 17.9%

The 5.3% FCF yield sits alongside a 13.5% ROIC and 7.7% year-over-year revenue growth, with net debt at 0.73× EBITDA and interest coverage above 11×, a clean balance sheet for an exploration and production company at this stage of the commodity cycle.

Three insiders filed Form 4 purchases during the June 22 period: Andres Felipe Mejia Cardona, Silvina Vatnick, and Sylvia Escovar Gomez, all adding shares within the same reporting window.

The 18.9 trailing P/E compresses the earnings yield to 5.3%, leaving only 0.7 percentage points of spread over the 10-year Treasury yield on a normalized basis, which narrows the margin for error if oil prices weaken before the August 6 earnings release.

2. KLA Corporation (KLAC)

Dividend yield: 4.0% | Payout ratio: 29.6% | 52w drawdown: 88.8%

The 12.4% FCF yield pairs with a 66.5% ROIC, 60.9% gross margin, and 23.9% year-over-year revenue growth, a rare combination of profitability and expansion in semiconductor capital equipment at a price 88.8% below the 52-week high of $2,060.

Bren D. Higgins filed two Form 4 purchases in early July (July 2 and July 6), and Mary Beth Wilkinson added shares on July 2, three insider buys within a five-day window.

The analyst consensus target of $1,855 implies a 705% upside from the current $230 price, a spread that reflects either a floor-level entry point or a structural revaluation in semiconductor equipment demand that has yet to materialize; the next earnings call on July 28 will clarify which scenario applies.

3. Newmont Corporation (NEM)

Dividend yield: 1.1% | Payout ratio: 15.7% | 52w drawdown: 30.1%

The 7.3% FCF yield and 29.9% ROIC sit alongside 21.3% revenue growth and 53.2% gross margins, with net debt negative at −0.20× EBITDA, a balance sheet that supports expansion or buybacks without leverage risk.

The 1.1% dividend yield is the lowest on this screen, with a 15.7% payout ratio that leaves room for distribution growth but offers little current income relative to the energy and pharma names that yield above 3%.

Peter Toth filed a Form 4 sell on July 6, the only insider transaction in the past 30 days and a net sell of 18,394 shares over six months, a signal that offsets the FCF yield strength and warrants attention when earnings land on July 23.

4. Novartis AG (NVS)

Dividend yield: 3.2% | Payout ratio: 64.7% | 52w drawdown: 11.6%

The 5.3% FCF yield and 16.0% ROIC combine with 75.8% gross margins and 9.6% revenue growth, a mature pharma profile that funds a 3.2% dividend yielding 64.7% of free cash flow without straining the balance sheet at 1.75× net debt to EBITDA.

Novartis won Health Canada approval for Vanrafia in IgA nephropathy and announced a collaboration with Chai Discovery to advance AI-driven antibody discovery, two pipeline expansion signals that extend the franchise beyond the current revenue base.

The analyst target of $153.87 implies only 2.1% upside from the $150.66 price, a valuation ceiling that reflects the mature growth profile and limits near-term capital appreciation relative to the drawdown opportunities elsewhere on this screen.

5. Biogen Inc. (BIIB)

Dividend yield: n/a | Payout ratio: 0.0% | 52w drawdown: 6.7%

The 6.9% FCF yield sits alongside 75.7% gross margins and 2.2% revenue growth, with net debt at 0.64× EBITDA and interest coverage of 6.8×, a balance sheet that supports pipeline investment without distribution pressure since Biogen pays no dividend.

Ten insider buys over six months resulted in a net positive position of three shares, with all transactions on the buy side and zero sells, a directional signal that aligns with the July 29 earnings release two weeks out.

Fresh tau-targeting ASO data presented at AAIC26 drove the stock down, and the estimated Q2 EPS of $2.02 on $2.4 billion in revenue will clarify whether the Alzheimer's franchise can stabilize commercial traction after the recent clinical readout disappointment.